Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q86VZ5
UPID:
SMS1_HUMAN
Alternative names:
Medulla oblongata-derived protein; Sphingomyelin synthase 1; Transmembrane protein 23
Alternative UPACC:
Q86VZ5; D3DWC4; Q68U43; Q6EKK0; Q75SP1
Background:
Phosphatidylcholine:ceramide cholinephosphotransferase 1, also known as Sphingomyelin synthase 1, plays a pivotal role at the Golgi apparatus. It catalyzes the reversible transfer of phosphocholine in sphingomyelin biosynthesis, influencing the balance between ceramide, sphingomyelin, and diacylglycerol. This balance is crucial for cell signaling, including mitogenic and proapoptotic pathways, and for the structural integrity of membrane rafts, which are essential for signal transduction and protein sorting.
Therapeutic significance:
Understanding the role of Phosphatidylcholine:ceramide cholinephosphotransferase 1 could open doors to potential therapeutic strategies.